AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3768247
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg day‐1 for 7 days)
Trial: 28675983
Drug: Intravenous fluid
RxNorm normalized name: Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fluid (IVF) supplementation (50 mL/kg over 8 hours)
Trial: 28675983
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution (ORS) (50 mL over 8 hours)
Trial: 18843118
Drug: GAD-alum (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (20 microg, subcutaneous injections on study days 1 and 30)
Trial: 18843118
Drug: Placebo (alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (alum alone, subcutaneous injections on study days 1 and 30)
Trial: 10348471
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 12.5 mg clozapine
Trial: 10348471
Drug: Chronic clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic clozapine treatment (39+/‐9 mg up to 50 mg) for 15.8+/‐7.7 months
Trial: 8598837
Drug: Induction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of labor with intravenous oxytocin
Trial: 8598837
Drug: Induction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of labor with vaginal prostaglandin E2 gel
Trial: 2058572
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (without fish-oil supplement)
Trial: 6337322
Drug: Decongestant-antihistamine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestant-antihistamine combination (pseudoephedrine hydrochloride, 4 mg/kg/day and chlorpheniramine maleate, 0.35 mg/kg/day)
Trial: 6337322
Drug: Decongestant-antihistamine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestant-antihistamine combination
Trial: 22842212
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of citalopram
Trial: 18001404
Drug: 10-day moxifloxacin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day moxifloxacin-based triple therapy (moxifloxacin 400 mg q.d., amoxicillin 1000 mg b.i.d., esomeprazole 20 mg b.i.d.)
Trial: 18001404
Drug: 2-week quadruple
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week quadruple therapy (esomeprazole 20 mg b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d., metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d.)
Trial: 15698450
Drug: CAPD with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAPD with a target creatinine clearance >/=60 L/week/1.73 m(2)
Trial: 15698450
Drug: Standard 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 4 x 2 L continuous ambulatory peritoneal dialysis (CAPD)
Trial: 7653482
Drug: Intermittent cyclic
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent cyclic etidronate (400 mg/d for 14 days followed by calcium 500 mg/d for 76 days)
Trial: 1232529
Drug: Melphalan and
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan and prednisone 0.6 mg/kg
Trial: 1232529
Drug: Melphalan and
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan and prednisone 0.3 mg/kg
Trial: 20373478
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tandospirone (TSP)
Trial: 20373478
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg diazepam (DZP)
Trial: 16536020
Drug: Oxygen-therapy with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-therapy with helmet
Trial: 30058112
Drug: Baricitinib 4
RxNorm normalized name: baricitinib 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib 4 mg/day
Trial: 30181533
Drug: EBD combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EBD combined with triamcinolone (50 mg/5 mL)
Trial: 26497691
Drug: Nicotine cigarettes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine cigarettes (8.9 mg)
Trial: 26497691
Drug: Placebo cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cigarettes (1.0 mg)
Trial: 10470633
Drug: Tramadol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (150 mg bolus + 250 mg infusion over 3 hours)
Trial: 10470633
Drug: Meperidine (112.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine (112.5 mg bolus + 187.5 mg infusion over 3 hours)
Trial: 30701467
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg thalidomide maintenance (Group B)
Trial: 30701467
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg thalidomide maintenance (Group C)
Trial: 28681218
Drug: Cisplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (75 mg/m2, day 1) with paclitaxel (80 mg/m2, days 1, 8, and 15) every 21 days as neoadjuvant chemotherapy (NAC) for 3 cycles before radical hysterectomy (RH).
Trial: 28681218
Drug: Cisplatin plus
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin plus dose-dense paclitaxel (dose-dense TP) for 3 cycles before and 2 cycles after radical hysterectomy (RH).
Trial: 24720402
Drug: Bixalomer (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bixalomer (1.5 g/day adjusted to a maximum of 7.5 g/day)
Trial: 24720402
Drug: Sevelamer hydrochloride
RxNorm normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer hydrochloride (3.0 or 6.0 g/day adjusted to a maximum of 9.0 g/day)
Trial: 16083710
Drug: telbivudine 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telbivudine 400 mg/day
Trial: 16083710
Drug: telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telbivudine 600 mg/day
Trial: 16083710
Drug: Comb400 (telbivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comb400 (telbivudine 400 mg/day + lamivudine 100 mg/day)
Trial: 16083710
Drug: Comb600 (telbivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comb600 (telbivudine 600 mg/day + lamivudine 100 mg/day)
Trial: 18520981
Drug: Minocycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline (200 mg/d)
Trial: 7011293
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets (0.96 grams) of Co-trimoxazole twice a day for one day
Trial: 7011293
Drug: Four tablets
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four tablets (1.92 grams) of Co-trimoxazole as a single dose
Trial: 7011293
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of Co-trimoxazole twice a day for seven days
Trial: 31747035
Drug: Positive valence
RxNorm normalized name: valencene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive valence system-focused cognitive behavioral therapy with inaudible high-frequency sound
Trial: 31747035
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy with placebo sound
Trial: 26692255
Drug: Serotonin reuptake
RxNorm normalized name: Selective serotonin reuptake inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin reuptake inhibitors (SRIs)
Trial: 9738752
Drug: Preoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative intravenous antibiotics followed by oral antibiotics for 5 days after surgery
Trial: 2470995
Drug: Isradipine 15
RxNorm normalized name: Isradipine
DrugBank: Isradipine (DB00270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isradipine 15 mg/day
Trial: 2470995
Drug: Isradipine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (various doses: 0, 2.5, 5, 7.5, or 10 mg twice daily)
Trial: 23316787
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of all three components
Trial: 23548251
Drug: Misoprostol 400
RxNorm normalized name: Misoprostol 400 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 400 μg per vaginally at 24 hours after mifepristone
Trial: 23548251
Drug: Mifepristone and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone and misoprostol combination at 48 hours interval
Trial: 16796988
Drug: Closed suction
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Closed suction drainage of the subcutaneous space
Trial: 10661480
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg daily with or without betaine 4 g per day for 12 weeks, followed by 1 or 5 mg of folic acid thereafter for 40 weeks.
Trial: 10661480
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid treatment for hyperhomocysteinemia.
Trial: 29465059
Drug: Glutaraldehyde-containing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutaraldehyde-containing agent (GCA) application
Trial: 24074810
Drug: Ketoconazole (KTCZ)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KTCZ) with low-dose cortisol
Trial: 24074810
Drug: Ketoconazole (KTCZ)
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoconazole (KTCZ) with high-dose cortisol
Trial: 21959825
Drug: Thiazide +
RxNorm normalized name: althiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide + Losartan 50 mg/day
Trial: 11789362
Drug: Thiazide 50
RxNorm normalized name: benzthiazide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide 50 mg/day
Trial: 12638027
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg/d for 3 months
Trial: 30563934
Drug: Afuresertib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afuresertib at 125 mg/day with intravenous paclitaxel (175 mg/m2) and carboplatin (AUC5) every 3 weeks for six cycles followed by maintenance afuresertib at 125 mg/day
Trial: 27706120
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray containing liposomes, vitamins A and E (experimental arm group I)
Trial: 27706120
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (sodium chloride 0.9%) (control arm group II)
Trial: 26525391
Drug: Polypharmacy (use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (use of five or more drugs)
Trial: 26525391
Drug: No polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No polypharmacy (less than five drugs)
Trial: 26525391
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of drugs
Trial: 22607295
Drug: Resin salve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resin salve treatment
Trial: 19641054
Drug: Pregabalin 300
RxNorm normalized name: pregabalin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 300 mg administered perioperatively, 12 hours apart.
Trial: 17620739
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) - 20 treatments at 2.0 ATA for 90 minutes
Trial: 16861258
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% (2.2 ml) heavy with clonidine (75 microg) in 0.5 ml normal saline 0.9% (BC)
Trial: 16861258
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% (2.2 ml) heavy with 0.5 ml normal saline 0.9% (B)
Trial: 2049311
Drug: Chlorambucil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorambucil (10 mg daily for six weeks, then alternating fortnights for 12 weeks) + Interferon-alpha 2b (2 x 10(6) U/m2 three times weekly for 18 weeks)
Trial: 6301364
Drug: Ceftriaxone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (250 mg, single intramuscular dose)
Trial: 6301364
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G (4.8 X 10(6) U, two intramuscular doses)
Trial: 20808298
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of aspirin (≥ 4 times/month)
Trial: 20808298
Drug: Heavy use
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy use of combined aspirin and ibuprofen (≥ 2 times/day) in males
Trial: 20808298
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of ibuprofen
Trial: 17950096
Drug: Losartan 100
RxNorm normalized name: LOSARTAN 100MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 100 mg + amlodipine 5 mg
Trial: 25516774
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg once daily
Trial: 12241530
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1.5 g daily in three doses for 3 weeks)
Trial: 10404801
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg orally once daily for 6 months (group 1)
Trial: 8583588
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group 2)
Trial: 8552122
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg pergolide
Trial: 8552122
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bromocriptine
Trial: 25877711
Drug: 0.1% bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% bromfenac sodium eye drops, twice a day for three days before surgery and one day after surgery
Trial: 23636449
Drug: Warfarin 1
RxNorm normalized name: warfarin 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 1 mg/day
Trial: 23636449
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant prophylaxis
Trial: 23636449
Drug: Anticoagulation (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation (both LMWH and Warfarin)
Trial: 8904740
Drug: Pregnanolone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnanolone (two different formulations)
Trial: 8904740
Drug: Placebo (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (not administered in this study)
Trial: 6406699
Drug: 40% zinc
RxNorm normalized name: ZINC OXIDE 40 g in 100 g TOPICAL CREAM [Diaper Rash Cream 40% ZINC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40% zinc oxide ointment
Trial: 6406699
Drug: Plain petrolatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain petrolatum ointment
Trial: 26718808
Drug: 10 IU
RxNorm normalized name: Thyrotropin 10 IU Injection Powder for Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 IU oxytocin in Uniject (intramuscular)
Trial: 25098777
Drug: Full-dose US
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose US group (0.5 ml/kg LA)
Trial: 25098777
Drug: 30% reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% reduced dose LA (0.35 ml/kg)
Trial: 25098777
Drug: 50% reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% reduced dose LA (0.25 ml/kg)
Trial: 25098777
Drug: 70% reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70% reduced dose LA (0.15 ml/kg)
Trial: 25098777
Drug: Neurostimulation alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurostimulation alone group (0.5 ml/kg LA)
Trial: 25098777
Drug: Full-dose group
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose group
Trial: 18706549
Drug: Long letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long letrozole therapy (n = 108; 219 cycles)
Trial: 18706549
Drug: Short letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short letrozole therapy (n = 110; 225 cycles)
Trial: 18706549
Drug: Long letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long letrozole therapy
Trial: 18706549
Drug: Short letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short letrozole therapy
Trial: 19001352
Drug: GIST (group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIST (group, individual, and staff therapy)
Trial: 16041534
Drug: biperiden (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: biperiden (2 mg)
Trial: 16041534
Drug: rivastigmine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rivastigmine (3 mg)
Trial: 10407599
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg monthly doses)
Trial: 2147752
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg once daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Trial: 2147752
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg twice daily (with doubling of dosage at week 6 if LDL-cholesterol > 1.40 g/l)
Trial: 7438715
Drug: Methionine enkephalin
RxNorm normalized name: Methionine Enkephalin
DrugBank: Metenkefalin (DB12668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine enkephalin analogue DAMME infusion
Trial: 30977273
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg NAC syrup, orally once daily at night for 7 consecutive days
Trial: 30977273
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered similarly to NAC
Trial: 22761293
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine for 7‐11 days
Trial: 16318659
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.5% 10 mg (Group I)
Trial: 16318659
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 0.5% 17.5 mg (Group II)
Trial: 12393618
Drug: ATT (alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATT (alternating triple therapy)
Trial: 8565029
Drug: Etodolac 400
RxNorm normalized name: etodolac 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etodolac 400 mg twice daily
Trial: 26353789
Drug: High-dose fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fish oil (4.5 g omega-3 fatty acids) 15 mL/day
Trial: 26353789
Drug: Low-dose fish
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fish oil (blend of fish oil and sunola oil; ratio of 1:9, 0.45 g omega-3 fatty acids) 15 mL/day
Trial: 23879825
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) in addition to conventional medical treatment
Trial: 20523087
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 on day 1 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm A)
Trial: 20523087
Drug: Carboplatin AUC
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC 5 on day 8 with gemcitabine 1,250 mg/m2 on days 1 and 8 (arm B)
Trial: 18444053
Drug: Maudsley model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maudsley model of family therapy for anorexia nervosa
Trial: 18444053
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for bulimia nervosa
Trial: 18444053
Drug: Other psychosocial
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other psychosocial interventions (family therapy, cognitive therapy, behavioral therapy)
Trial: 8823423
Drug: Additional doses
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional doses of rifampicin, pyrazinamide and streptomycin every 4 weeks in the continuation phase (114 patients)
Trial: 8823423
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen without additional doses (113 patients)